Predictive Model of Objective Response to Nivolumab Monotherapy for Advanced Renal Cell Carcinoma by Machine Learning Using Genetic and Clinical Data: The SNiP-RCC Study.

Journal: JCO clinical cancer informatics
PMID:

Abstract

PURPOSE: Anti-PD-1 antibodies are widely used for cancer treatment, including in advanced renal cell carcinoma (RCC). However, the therapeutic response varies among patients. This study aimed to predict tumor response to nivolumab anti-PD-1 antibody treatment for advanced RCC by integrating genetic and clinical data using machine learning (ML).

Authors

  • Masaki Shiota
    Department of Urology, Kyushu University, Fukuoka, Japan.
  • Shota Nemoto
    Industrial & Digital Business Unit, Hitachi Ltd, Chiyoda-ku, Tokyo, Japan.
  • Ryo Ikegami
    Industrial and Digital Business Unit, Hitachi, Ltd, Tokyo, Japan.
  • Tokiyoshi Tanegashima
    Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Leandro Blas
    Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Hideaki Miyake
    Department of Urology Hamamatsu University School of Medicine Hamamatsu Japan.
  • Masayuki Takahashi
    The Department of Urology, Tokushima University Graduate School of Biomedical Sciences.
  • Mototsugu Oya
    Department of Urology Keio University School of Medicine Tokyo Japan.
  • Norihiko Tsuchiya
    Department of Urology, Yamagata University School of Medicine, Yamagata.
  • Naoya Masumori
    Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan.
  • Keita Kobayashi
    Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan.
  • Wataru Obara
    Department of Urology, Iwate Medical University, Yahaba, Japan.
  • Nobuo Shinohara
    Department of Renal and Genitourinary Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
  • Kiyohide Fujimoto
    Department of Urology, Nara Medical University, Kashihara, Nara, Japan.
  • Masahiro Nozawa
    Department of Urology, Kindai University Faculty of Medicine, Osaka, Japan.
  • Kojiro Ohba
    Department of Urology and Renal Transplantation, Nagasaki University Hospital, Nagasaki, Japan.
  • Chikara Ohyama
    Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
  • Katsuyoshi Hashine
    Department of Urology, National Hospital Organization Shikoku Cancer Center, Ehime, Japan.
  • Shusuke Akamatsu
    Department of Urology, Kyoto University Graduate School of Medicine, 54 Shogoin-kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
  • Takanobu Motoshima
    Department of Urology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
  • Koji Mita
    The Department of Urology, Hiroshima City Asa Hospital.
  • Momokazu Gotoh
    Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Shuichi Tatarano
    Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
  • Masato Fujisawa
    Division of Urology Kobe University Graduate School of Medicine Kobe Japan.
  • Yoshihiko Tomita
    Department of Urology and Molecular Oncology, Graduate School of Medicine and Dental Sciences, Niigata University, Niigata, Japan.
  • Shoichiro Mukai
    Department of Urology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
  • Keiichi Ito
    Department of Urology, National Defense Medical College, Saitama, Japan.
  • Masatoshi Eto
    Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.